vorinostat Clinical Research Trials

A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer

TITLE:A Phase II non-comparative study of paclitaxel plus carboplatin in combination with Vorinostat in patients with advanced, recurrent epithelial ovarian cancer. INDICATION:Second-line

carboplatin

fallopian tube

ovarian epithelial cancer

paclitaxel

recurrent ovarian cancer

10 views
07 Nov, 2020
1 location

Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease

death. The current best treatment for Cushing s disease is surgery. If surgery does not work or if the tumor returns, there are no more good treatment options. Vorinostat, which is approved to treat a

pituitary

lymphoma

cushing's syndrome

ACTH

hormones released

21 views
03 Mar, 2021
1 location

Study of Tinostamustine First-in-Class Alkylating HDACi Fusion Molecule in Relapsed/Refractory Hematologic Malignancies

This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.

t-cell prolymphocytic leukemia

mycosis

angioimmunoblastic t-cell lymphoma

alemtuzumab

refractory multiple myeloma

0 views
27 Jan, 2021
25 locations

MIBG With Dinutuximab +/- Vorinostat

2 pediatric dose. An expansion cohort of an additional 6 patients will then be enrolled. If tolerable, vorinostat will then be added to the third dose level. A 6 patient expansion cohort may then be

avid

dinutuximab

ganglioneuroblastoma

iobenguane

vorinostat

38 views
29 Jan, 2021
11 locations

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

The objective of this study is to evaluate the maximum tolerated (MTD) of vorinostat used in combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation (alloHCT

transplant conditioning

graft versus host disease

cancer

azacitidine

cell transplantation

2 views
25 Jan, 2021
2 locations

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

The purpose of this research study is to test the safety and tolerability of the combination treatment of the investigational drugs vorinostat and pembrolizumab, in combination with chemotherapy

karnofsky performance status

gliosarcoma

malignant glioma

cancer

temozolomide

67 views
26 Jan, 2021
1 location

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective

drug combinations

isof

growth factor

blood transfusion

g-csf

3 views
24 Jan, 2021
1 location

Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease

This Clinical Trial is an open, non-randomized Phase Ib study to determine the maximal tolerable dose (MTD) of Vorinostat in Alzheimer disease (AD) patients between (including) 55 and 90 years

mini-mental state examination

mental state examination

25 views
23 Jan, 2021
4 locations

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

The main purpose of this study is to see whether the combination of two drugs called pembrolizumab and vorinostat can help people with advanced lung cancer. Researchers also want to find out if

solid tumour

stage iv non-small cell lung cancer

ROS1

chemoradiotherapy

proto-oncogene tyrosine-protein kinase ros

0 views
26 Jan, 2021
1 location

Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours. Each

1 views
25 Jan, 2021
1 location

Filter By

Found 21 clinical trials